Open access
Sep 2026
Enhanced CD33 CAR-NK cells secreting anti-CD73scFv overcome adenosine-mediated immunosuppression and improve anti-AML efficacy
The CD33-CD73 dual-targeting CAR-NK platform synergistically targets AML cells and the adenosine-rich TME, exhibiting superior anti-leukemia efficacy and provides a translational blueprint for TME-targeted therapies in other cancers.
Lu Wang, S. Gong, Jun Wang et al.
· Journal for ImmunoTherapy of... · 0 citations